Literature DB >> 22178719

Dopamine-₃ receptor modulates intraocular pressure: implications for glaucoma.

Claudio Bucolo1, Gian Marco Leggio, Adriana Maltese, Alessandro Castorina, Velia D'Agata, Filippo Drago.   

Abstract

The aim of the present study was to investigate the role of D₃ receptor on intraocular pressure regulation using WT and KO D₃R⁻/⁻ mice. Both mice were used with normal eye pressure or steroid-induced ocular hypertension. As measured by tonometry, the topical application of 7-OH-DPAT, a dopamine D₃-preferring receptor agonist, significantly decreased, in a dose-dependent manner, the intraocular pressure in WT mice both in an ocular normotensive group and an ocular hypertensive group. Pretreatment with U-99194A, a D₃ receptor antagonist, reverted 7-OH-DPAT induced ocular hypotension in WT mice. No change of intraocular pressure was observed after topical application of 7-OH-DPAT in KO D₃R⁻/⁻ mice. PCR analysis demonstrated the presence of all dopamine receptor genes in eye tissues obtained from WT mice, and the lack of D₃R mRNAs in KO mice. The present study identified the D₃R subtype as the most important receptor of the dopaminergic system to modulate intraocular pressure with relevant implications for glaucoma that represents one of the most crippling optic neuropathies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178719     DOI: 10.1016/j.bcp.2011.11.031

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  Understanding the role of dopamine in cancer: past, present and future.

Authors:  Christopher E Grant; Amy L Flis; Bríd M Ryan
Journal:  Carcinogenesis       Date:  2022-06-27       Impact factor: 4.741

2.  Robust Dopaminergic Differentiation and Enhanced LPS-Induced Neuroinflammatory Response in Serum-Deprived Human SH-SY5Y Cells: Implication for Parkinson's Disease.

Authors:  Aram Niaz; Jocelyn Karunia; Mawj Mandwie; Kevin A Keay; Giuseppe Musumeci; Ghaith Al-Badri; Alessandro Castorina
Journal:  J Mol Neurosci       Date:  2020-08-13       Impact factor: 3.444

3.  Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation.

Authors:  Chiara Bianca Maria Platania; Salvatore Salomone; Gian Marco Leggio; Filippo Drago; Claudio Bucolo
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

Review 4.  Novel Therapeutics in Glaucoma Management.

Authors:  Claudio Bucolo; Chiara Bianca Maria Platania; Filippo Drago; Vincenza Bonfiglio; Michele Reibaldi; Teresio Avitabile; Maurizio Uva
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

5.  Ocular drug delivery: a clue from nanotechnology.

Authors:  Claudio Bucolo; Filippo Drago; Salvatore Salomone
Journal:  Front Pharmacol       Date:  2012-10-25       Impact factor: 5.810

Review 6.  Role of dopaminergic receptors in glaucomatous disease modulation.

Authors:  Nicola Pescosolido; Francesco Parisi; Paola Russo; Giuseppe Buomprisco; Marcella Nebbioso
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

7.  Influence of the hypothalamic arcuate nucleus on intraocular pressure and the role of opioid peptides.

Authors:  Ji Jin; Guo-xu Xu; Zhi-lan Yuan
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

8.  Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells.

Authors:  Sarah Thomas Broome; Teagan Fisher; Alen Faiz; Kevin A Keay; Giuseppe Musumeci; Ghaith Al-Badri; Alessandro Castorina
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

Review 9.  Crosstalk Between Dysfunctional Mitochondria and Inflammation in Glaucomatous Neurodegeneration.

Authors:  Assraa Hassan Jassim; Denise M Inman; Claire H Mitchell
Journal:  Front Pharmacol       Date:  2021-07-21       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.